Keyword: Roche Venture Fund

Vivet Therapeutics

Vivet is harnessing the power of gene therapy to target Wilson disease and other rare genetic disorders as it looks to shake off a tough few years for research and sales in the gene therapy field.

Swiss majors Roche and Novartis back gene therapy upstart

Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an executive team made up of Novartis, Sanofi and Gensight veterans, as the company looks to get to work on its gene therapies for a host of rare diseases.

Pivotal bioVenture Partners closes $300M early biotech fund

The Nan Fung Group’s venture capital firm Pivotal bioVenture Partners has raised its first fund, totaling $300 million, as it looks to help early-stage life science startups get off the ground. Its founder tells me she aims to not chase investment trends but seek out solid science and management teams.

PTC, Roche head into PhII SMA test

As Roche continues to try to hit all the bases in this rare disease, its partner PTC Therapeutics has started a midstage study for its candidate against certain forms of spinal muscular atrophy.